-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Maintains Overweight on 4D Molecular Therapeutics, Lowers Price Target to $38

Benzinga·05/09/2025 12:16:55
Listen to the news
Barclays analyst Gena Wang maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Overweight and lowers the price target from $45 to $38.